Celldex Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Celldex Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 39.5% bzw. 69.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 43.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -56.3% betragen.

Wichtige Informationen

39.5%

Wachstumsrate der Gewinne

43.74%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	25.4%
Wachstumsrate der Einnahmen	69.8%
Zukünftige Eigenkapitalrendite	-56.26%
Analystenabdeckung	Good
Zuletzt aktualisiert	08 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Analyseartikel • May 06

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Apr 22

Celldex Therapeutics: Strong Pipeline But Uncertainties Remain

Summary We initiate a Hold rating for Celldex Therapeutics due to uncertainties surrounding barzolvolimab's mid-2025 data readouts and potential market positioning challenges. Barzolvolimab's Phase 3 trials target chronic spontaneous urticaria, chronic inducible urticaria, eosinophilic esophagitis, prurigo nodularis, and atopic dermatitis, with mixed competitive prospects. Celldex’s cash runway extends into 2027, but potential delays or hurdles could necessitate earlier fundraising, exerting downward pressure on valuation. Investment risks include trial failures, commercial uptake challenges, resource-intensive commercialization, potential side effects, and broader macroeconomic factors affecting funding and share price. Read the full article on Seeking Alpha

Analyseartikel • Jan 28

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analyseartikel • Jun 07

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

Key Insights Celldex Therapeutics to hold its Annual General Meeting on 13th of June Total pay for CEO Anthony Marucci...

Analyseartikel • Jun 05

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyseartikel • Jul 07

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analyseartikel • Apr 21

An Intrinsic Calculation For Celldex Therapeutics, Inc. (NASDAQ:CLDX) Suggests It's 34% Undervalued

Key Insights Celldex Therapeutics' estimated fair value is US$54.52 based on 2 Stage Free Cash Flow to Equity Celldex...

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:CLDX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	142	-280	-196	-152	9
12/31/2027	11	-373	-281	-296	9
12/31/2026	2	-334	-281	-273	9
3/31/2026	1	-284	-226	-222	N/A
12/31/2025	2	-259	-214	-211	N/A
9/30/2025	3	-225	-182	-179	N/A
6/30/2025	6	-200	-188	-186	N/A
3/31/2025	8	-179	-173	-172	N/A
12/31/2024	7	-158	-160	-158	N/A
9/30/2024	10	-154	-160	-158	N/A
6/30/2024	8	-150	-123	-121	N/A
3/31/2024	6	-145	-121	-119	N/A
12/31/2023	7	-141	-109	-107	N/A
9/30/2023	4	-125	-98	-97	N/A
6/30/2023	3	-113	-114	-113	N/A
3/31/2023	3	-119	-110	-108	N/A
12/31/2022	2	-112	-106	-104	N/A
9/30/2022	1	-106	-98	-96	N/A
6/30/2022	1	-100	-79	-78	N/A
3/31/2022	4	-77	-69	-67	N/A
12/31/2021	5	-71	-62	-61	N/A
9/30/2021	8	-72	-53	-52	N/A
6/30/2021	9	-66	-48	-47	N/A
3/31/2021	5	-64	-48	-46	N/A
12/31/2020	7	-60	-42	-40	N/A
9/30/2020	5	-48	-48	-46	N/A
6/30/2020	4	-46	-47	-45	N/A
3/31/2020	5	-46	-46	-45	N/A
12/31/2019	4	-51	N/A	-46	N/A
9/30/2019	4	-50	N/A	-51	N/A
6/30/2019	5	-46	N/A	-54	N/A
3/31/2019	7	-50	N/A	-60	N/A
12/31/2018	10	-151	N/A	-75	N/A
9/30/2018	11	-146	N/A	-79	N/A
6/30/2018	14	-165	N/A	-89	N/A
3/31/2018	15	-177	N/A	-93	N/A
12/31/2017	13	-93	N/A	-100	N/A
9/30/2017	11	-121	N/A	-101	N/A
6/30/2017	9	-125	N/A	-100	N/A
3/31/2017	7	-128	N/A	-113	N/A
12/31/2016	7	-129	N/A	-113	N/A
9/30/2016	7	-129	N/A	-106	N/A
6/30/2016	6	-131	N/A	-110	N/A
3/31/2016	6	-132	N/A	-101	N/A
12/31/2015	5	-127	N/A	-99	N/A
9/30/2015	5	-126	N/A	-107	N/A
6/30/2015	5	-122	N/A	-106	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CLDX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CLDX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CLDX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CLDXDie Einnahmen des Unternehmens (69.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (11.6% pro Jahr).

Hohe Wachstumseinnahmen: CLDXDie Einnahmen des Unternehmens (69.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CLDX wird voraussichtlich in 3 Jahren unrentabel sein.

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/05/12 22:13
Aktienkurs zum Tagesende	2026/05/12 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Celldex Therapeutics, Inc. wird von 22 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Etzer Darout	Barclays
Edward Nash	Canaccord Genuity
Kristen Kluska	Cantor Fitzgerald & Co.

Celldex Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 19%

Price target decreased by 7.9% to US$53.85

Consensus revenue estimates fall by 18%

Price target decreased by 11% to US$57.58

Consensus revenue estimates increase by 15%, EPS downgraded

Consensus revenue estimates increase by 65%

Recent updates

New major risk - Revenue size

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Celldex Advances Barzolvolimab Trials With Strong Cash Position After Q1 Earnings Miss

Celldex Therapeutics, Inc., Annual General Meeting, Jun 25, 2026

New minor risk - Shareholder dilution

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $300.005 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering.

Celldex Therapeutics, Inc. Presents Positive Data From Phase 2 Chronic Spontaneous Urticaria And Phase 2 Cold Urticaria And Symptomatic Dermographism Studies Demonstrating Rapid, Profound And Durable Improvements In Patient Quality Of Life At AAD 2026

Celldex Presents Positive Data Demonstrating Barzolvolimab Ret Treatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (Coldu) and Symptomatic Dermographism (Sd) Further Demonstrating First Exposure in Patients with Barzolvolimab

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (Csu) and Phase 2 Cold Urticaria (Coldu) and Symptomatic Dermographism (Sd) Studies Further Demonstrating First-In-Class and Best-Disease

Full year 2025 earnings: EPS and revenues miss analyst expectations

Celldex Completes Enrollment in Global Phase 3 Studies (Embarq-Csu1 and Embarq-Csu2) of Barzolvolimab in Chronic Spontaneous Urticaria

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

Chief Commercial Officer & Senior VP exercised options and sold US$490k worth of stock

Consensus revenue estimates fall by 19%

Third quarter 2025 earnings released: US$1.01 loss per share (vs US$0.64 loss in 3Q 2024)

Celldex Therapeutics, Inc. Announces Executive Changes

Celldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria Study

Celldex Therapeutics, Inc. Announces Initial Positive Results from Phase 1 Trial of CDX-622

Price target decreased by 7.9% to US$53.85

Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Celldex Therapeutics, Inc.(NasdaqCM:CLDX) dropped from Russell 2500 Growth Index

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

Celldex Therapeutics Announces Election of Denice Torres to Its Board of Directors

Consensus revenue estimates fall by 18%

Price target decreased by 11% to US$57.58

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in This Difficult to Treat Disease

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

Celldex Therapeutics, Inc., Annual General Meeting, Jun 05, 2025

Celldex Therapeutics: Strong Pipeline But Uncertainties Remain

Now 20% overvalued

Consensus revenue estimates increase by 15%, EPS downgraded

Celldex Therapeutics, Inc. Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life At Aaaai 2025

Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat

Here's Why We're Not Too Worried About Celldex Therapeutics' (NASDAQ:CLDX) Cash Burn Situation

Now 25% undervalued after recent price drop

New major risk - Revenue and earnings growth

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases

Founder recently bought US$308k worth of stock

Consensus revenue estimates increase by 65%

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Announces Positive Results from its Phase 2 Clinical Trial of Barzolvolimab

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 65%, EPS downgraded

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Celldex Therapeutics, Inc. Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria

Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria

Price target decreased by 7.6% to US$65.38

Senior VP & Chief Medical Officer recently sold US$1.6m worth of stock

Chief Commercial Officer & Senior VP notifies of intention to sell stock

Here's Why Celldex Therapeutics, Inc.'s (NASDAQ:CLDX) CEO Compensation Is The Least Of Shareholders' Concerns

We Think Celldex Therapeutics (NASDAQ:CLDX) Can Afford To Drive Business Growth

Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024

Senior VP recently sold US$341k worth of stock

Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis

Consensus revenue estimates decrease by 20%, EPS upgraded

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Celldex Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Celldex Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $400.44 million.

Celldex Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Price target increased by 9.7% to US$69.43

Celldex Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 26, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind